Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Board Authorizes $100M Share Repurchase

NEW YORK (GenomeWeb News) – Illumina today said that its board of directors has authorized the repurchase of up to $100 million of the firm's outstanding common stock.

Illumina said that the shares may be purchased either on the open market or under a 10b5-1 trading program, which enables the company to purchase its shares at times when it otherwise might be prevented from doing so under insider trading laws or self-imposed trading blackout periods. The firm said that purchases will be funded through its existing cash balances.

As of the end of its third quarter, Illumina held $238.5 million in cash and cash equivalents.

"Considering the strength of our balance sheet and our prospects for continued strong cash generation from our operations, this repurchase program is an effective means to return value to our shareholders," Illumina President and CEO Jay Flatley said in a statement.

Illumina recently completed a $75 million share repurchase program that was announced in August.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.